替吉奥联合伊立替康治疗结肠癌患者的效果及对腹泻的影响

The Effect of Tegafur Combined with Irinotecan in the Treatment of Colon Cancer and its Effects on Diarrhea

目的 探讨替吉奥联合伊立替康治疗结肠癌患者的效果及对腹泻的影响。方法 选取2018年6月至2020年1月于沈阳医学院附属中心医院接受治疗的结肠癌84例作为研究对象,按治疗方案不同分为对照组与观察组,各42例。对照组单用替吉奥治疗,观察组采用替吉奥联合伊立替康治疗。比较两组患者临床治疗效果、不良反应、生存期,血清基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平。结果 观察组治疗有效率为52.4%,高于对照组的21.4%(P<0.05);观察组不良反应发生率为40.5%,对照组为38.1%,差异无统计学意义(P>0.05);干预后两组血清MMP-9及VEGF水平改善,观察组血清MMP-9水平低于对照组,血清VEGF水平高于对照组,差异有统计学意义(P<0.05);观察组治疗后6、9、12个月生存率高于对照组,平均生存期长于对照组,差异有统计学意义(P<0.05)。结论 对结肠癌患者施以替吉奥联合伊立替康方案治疗,利于临床疗效提升,还可改善MMP-9以及VEGF水平,延长患者生存期,且不会增加药物不良反应。

Objective To investigate the effects of tegafur combined with irinotecan in the treatment of colon cancer and its influence on diarrhea. Methods A total of 84 patients with colon cancer who received treatment in the Affiliated Central Hospital of Shenyang Medical College from June 2018 to January 2020 were selected as research subjects, and they were divided into control group and observation group according to different treatment regimens, with 42 cases in each group. The control group was treated with tegafur alone, and the observation group was treated with tegafur combined with irinotecan. Clinical treatment effect, adverse reactions, survival, serum matrix metalloproteinase-9(MMP-9) and vascular endothelial growth factor(VEGF) levels were compared between 2 groups. Results The effective rate of clinical treatment in the observation group was 52.4%, which was higher than 21.4% of the control group(P<0.05);the total incidence of adverse reactions in the observation group was 40.5%, and the control group was 38.1%. There was no significant difference between the 2 groups(P>0.05);MMP-9 levels and VEGF levels in the 2 groups improved after medication, the MMP-9 level in the observation group was lower than the control group, and the VEGF level was higher than the control group(P<0.05);The survival rate of the observation group at 6, 9 and 12 months after treatment was higher than that of the control group, and the average survival time was longer than that of the control group(P<0.05).Conclusion The treatment of colon cancer patients with tegafur combined with irinotecan can not only improve the clinical efficacy,but also improve the levels of MMP-9 and VEGF, prolong the survival time of patients, and will not increase adverse drug reactions.